AFP and hepatocellular carcinoma: Subsequently, the subgroup of IM-HCC patients who benefit from TACE was identified through numerous criteria, including the Assessment for Retreatment with TACE (ART) score (6), the alpha-fetoprotein (AFP), BCLC, Child–Pugh, and response (ABCR) score (7), and the albumin–bilirubin (ALBI) grade (8), among others.